Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer

Figures & data

Table 1 Anti-neoplastics with single-agent activity (objective responses >10%) in platinum-resistant ovarian cancer (platinum-free interval <6 months) (listed in alphabetical order)

Altretamine

Bevacizumab

Docetaxel

Epirubicin

Etoposide (oral, every-21-day schedule)

Gemcitabine

Ifosfamide

Irinotecan

Paclitaxel (every-3-week or weekly schedule)

PLD

Pemetrexate

Tamoxifen

Topotecan

Vinorelbine

Abbreviation: PLD, pegylated liposomal doxorubicin.

Table 2 Trials involving single agent PLD in epithelial ovarian cancer (median PFS and overall survival)

Patient population	PLD	(Other agent)
Gordon et al^Citation17,Citation20		Topotecan
	Dose/schedule: 50 mg/m^2 q-28 d	Dose/schedule: 1.5 m/m^2 q-21 d
Platinum-sensitive	PFS: 28.9 weeks; OS: 108 weeks	PFS: 23.3 weeks; OS: 71.1 weeks
Platinum-resistant	PFS: 9.1 weeks; OS: 35.6 weeks	PFS: 13.6 weeks; OS: 41.3 weeks
Ferrandina et al^Citation25		Gemcitabine
Platinum-resistant	Dose/schedule: 40 mg/m^2 q-28 d	Dose/schedule: 1,000 mg/m^2 day 1,8,15 q-28 d
	PFS: 16 weeks; OS: 56 weeks	PFS: 20 weeks; OS: 51 weeks
Mutch et al^Citation24		Gemcitabine
	Dose/schedule: 50 mg/m^2 q-28 d	Dose/schedule: 1000 mg/m^2 day 1,8 q-21 d
	PFS: 3.1 months; OS: 13.5 months	PFS: 3.6 months; OS: 12.7 months

Abbreviations: OS, overall survival; PLD, pegylated liposomal doxorubicin; PFS, progression-free survival.

Table 3 PLD or topotecan versus canfosfamide as third-line chemotherapy of ovarian cancer²⁶

Treatment	Progression-free survival (median)	Overall survival (median)
PLD or topotecan	4.3 months	13.5 months
Canfosfamide	2.3 months	8.5 months

Note: P < 0.01.

Abbreviation: PLD, pegylated liposomal doxorubicin.

Table 4 Carboplatin/PLD versus carboplatin/paclitaxel as initial chemotherapy of ovarian cancer³⁰

Treatment	Progression-free survival (median)^a	Overall survival (median)^b
Carboplatin/PLD	19.0 months	61.6 months
Carboplatin/paclitaxel	16.8 months	53.2 months

Notes:

a P = 0.58;

b P = 0.32.

Abbreviation: PLD, pegylated liposomal doxorubicin.

Table 5 Carboplatin/PLD versus carboplatin/paclitaxel or single agent carboplatin as second-line chemotherapy of ovarian cancer

Study	Treatment	Progression-free survival (median)	Overall survival (median)	Allergic/hypersensitivity reactions (% of patients developing)
Pujade-Lauraine et al^Citation31	Carboplatin/PLD	11.3 months	(too early to report)	5.6%
	Carboplatin/Paclitaxel	9.4 months (P = 0.005)		18.8%
Markman et al^Citation32	Carboplatin/PLD	12 months	31 months	0% (0 of 31 patients)
	Carboplatin (single agent)	8 months (P = 0.02)	18 months (P = 0.2)	30% (9 of 30 patients)

Abbreviation: PLD, pegylated liposomal doxorubicin.

Table 6 PLD/trabectedin versus single agent PLD as second-line chemotherapy of ovarian cancer³³

	PLD	PLD/trabectedin
Platinum-resistant
Progression-free survival (median)	3.7 months	4.0 months (P = 0.75)
“Modestly” platinum-sensitive
Progression-free survival (median)	7.5 months	9.2 months (P = 0.017)
Total patient population
Progression-free survival (median)	5.8 months	7.3 months (P = 0.019)

Abbreviation: PLD, pegylated liposomal doxorubicin.

GordonANFleagleJTGuthrieDRecurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ Clin Oncol2001193312332211454878

 PubMed Web of Science ®Google Scholar

GordonANTondaMSunSLong-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a Phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecol Oncol2004951815385103

 PubMed Web of Science ®Google Scholar

FerrandinaGLudovisiMLorussoDPhase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerJ Clin Oncol20082689089618281662

 PubMed Web of Science ®Google Scholar

MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol2007252811281817602086

 PubMed Web of Science ®Google Scholar

VergoteIFinklerNdel CampoJPhase 3 randomized study of canfosfamide (Telcyda®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancerEur J Cancer2009452324233219515553

 PubMed Web of Science ®Google Scholar

PignataSScambiaGSavareseACarboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin in patients with advanced ovarian cancer: final analysis of the MITO-2 randomized multicenter trialJ Clin Oncol20102818s952a

 Google Scholar

Pujade-LauraineEWagnerUAavall-LundqvistEPegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapseJ Clin Oncol2010283323332920498395

 PubMed Web of Science ®Google Scholar

MarkmanMMoonJWilczynskiSSingle agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) Phase 3 randomized trialGynecol Oncol201011632332520044128

 PubMed Web of Science ®Google Scholar

MonkBJHerzogTJKayeSBTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancerJ Clin Oncol2010283107311420516432

 PubMed Web of Science ®Google Scholar